The European Medicines
Agency’s Pharmacovigilance
Risk Assessment Committee has
given the all clear to the human
papillomavirus (HPV) vaccine
following a detailed scientific
review of the evidence surrounding
reports of two syndromes, complex
regional pain syndrome (CRPS) and
postural orthostatic tachycardia
syndrome (POTS) in young women
vaccinated against HPV.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 09 Nov 15
To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Nov 15
